波士顿科学已正式签约明年第9届进博会

Core Insights - Boston Scientific has signed up for the 9th China International Import Expo (CIIE) in 2024, marking its seventh consecutive participation, reflecting its evolving role as a "new foreign enterprise" in China [1][3] Group 1: Company Strategy and Innovation - The company aims to shift from merely introducing global advanced technologies to co-creating value locally, embedding Chinese clinical needs into the global R&D system [1][3] - Boston Scientific will showcase over 80 innovative products at the expo, covering various medical fields, with 6 products making their debut [2][3] - Since its participation began, 22 products have transitioned from exhibition to commercialization, with a new manufacturing base in Shanghai expected to start mass production by 2026 [3] Group 2: AI and Digital Initiatives - The company launched the first medical device knowledge graph and a digital education platform, eLibrary 2.0, which includes a comprehensive medical knowledge base and an AI-driven question-answering system [5] - AI is being integrated into core product lines, such as the HeartLogic heart failure monitoring technology, which can predict potential heart failure events up to 34 days in advance and reduce hospitalization rates by 67% [5] Group 3: Clinical Collaboration and Education - Boston Scientific hosted a forum on stroke prevention and TCAR (Transcarotid Artery Revascularization) techniques, engaging top clinical experts to discuss advancements in stroke treatment [6] - The company emphasizes its commitment to innovation in the carotid artery stenosis treatment field, aiming to enhance the stroke prevention system in China through technological and academic collaboration [6]